Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

  title={Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.},
  author={Delphine Planas and David Veyer and Artem Baidaliuk and Isabelle Staropoli and Florence Guivel-Benhassine and Maaran Michael Rajah and Cyril Planchais and Françoise Porrot and Nicolas Robillard and Julien Puech and Matthieu Prot and Floriane Gallais and Pierre Gantner and Aur{\'e}lie Velay and Julien Le Guen and Najibi Kassis-Chikhani and Dhiaeddine Edriss and Laurent B{\'e}lec and Aymeric S{\`e}ve and Laura Courtellemont and H{\'e}l{\`e}ne P{\'e}r{\'e} and Laurent Hocqueloux and Samira Fafi-Kremer and Thierry Prazuck and Hugo Mouquet and Timoth{\'e}e Bruel and Etienne Simon-Lori{\`e}re and F{\'e}lix A. Rey and Olivier Schwartz},
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1-5. It has since then become dominant in some indian regions and UK and further spread to many countries6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), harbouring diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential. B.1.617.2, also termed variant Delta, is believed to spread faster than other variants… 

Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis

Nb22-Fc, among the previously reported nanobodies, exhibited 8.4-fold increased neutralization potency against Delta variant with an IC50 value of 0.41 ng/ml (5.13 pM) relative to Alpha variant, and crystal structural analysis reveals that Nb22 on SARS-CoV-2 RBD effectively blocks the binding of RBD to ACE2 during virus infection.

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination

The antibody neutralization capacity against the RBD of SARS-CoV-2 variants Alpha, Gamma, Epsilon, Kappa, and Delta is determined in a cohort of healthcare workers naturally infected or receiving COVID-19 mRNA vaccines from Moderna or Pfizer-BioNTech.

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants

A previously uncharacterized class of N-terminal domain-directed human neutralizing monoclonal antibodies cross-reacting with several variants of concern is described, revealing a possible target for vaccine development.

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance

This study sought to determine whether Delta Plus and Delta-V differ from the Delta variant regarding cell entry and neutralization sensitivity by using rhabdoviral pseudotypes, which are adequate models for cell entry of SARS-CoV-2, and previously described monoclonal antibodies and sera/plasma from infected or BNT162b2/Comirnaty vaccinated individuals.

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

The results indicate that the current mRNA-based vaccines will likely remain effective in protecting against B.1.617 variants, and that the P681R substitution confers efficient cleavage of B. 1.617.1 and AY.2 variants.

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants

Some of the most promising broadly neutralizing antibodies obtained from plasma of patients that recovered from early variants of SARS-CoV-2 that may be effective against emerging new variants of the virus are reviewed.

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy

It is shown that SARS-CoV-2 variants can elicit polyclonal antibodies with different immunodominance hierarchies and that neutralization by these antibodies is notably less affected by mutations at residue 484.

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients

It is highlighted that the BNT162b2 vaccine stimulates a humoral response able to neutralize all tested SARS-CoV-2 variants, thus suggesting a prominent role in mitigating the impact of the Sars-Cov-2 pandemic in real-world conditions.



SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough

In an analysis of over 130 SARS-CoV-2 infected healthcare workers across three centres in India during a period of mixed lineage circulation, substantially reduced ChAdOx-1 vaccine efficacy against B.617.1.2 Delta variant warrants continued infection control measures in the post-vaccination era.

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.

The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.

The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies.

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.

Therefore, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels.

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD are solved and rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use are provided.

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Complete maps of SARS-CoV-2 mutations that escape the Regeneron monoclonal antibody cocktail help explain viral evolution in a treated patient and enable interpretation of the consequences of mutations observed during viral surveillance.